Search clinical trials for: SGLT2i

Total 143 results

University of Chicago

Recruiting

HF Patients With LVADs Being Treated With SGLT2i

Heart Failure With Reduced Ejection Fraction

United States
University of Chicago

Terminated

The Hemodynamic Effects of SGLT2i in Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

United States
Universidade Federal do Ceará
Hospital de Messejana

Not yet recruiting

Impact of SGLT2 Inhibitors in Heart Transplant Recipients

Transplant; Failure, Heart | Rejection Heart Transplant | Cardiac Allograft Vasculopathy
Academisch Medisch Centrum - Universiteit van Amsterdam...
ZonMw: The Netherlands Organisation for Health Research and Development

Recruiting

proMoting Effective Renoprotection in Cardiac sURgery Patients by Inhibition of SGLT-2 (MERCURI-2)

Acute Kidney Injury | Cardiac Surgery | Sodium-Glucose Transporter 2 Inhibitor

Netherlands
Boehringer Ingelheim

Active, not recruiting

Non-interventional Study (NIS) on Sodium-glucose Co-transporter-2 Inhibitors (SGLT2i) Use in France

Diabetes Mellitus, Type 2

France
Jeil Pharmaceutical Co., Ltd.

Not yet recruiting

Evaluation of Efficacy and Safety When Administered JP-2266 in Type 2 Diabetes Patients

Type 2 Diabetes Mellitus

Korea, Republic of
Assistance Publique - Hôpitaux de Paris

Active, not recruiting

Treatment of IgA Nephropathy According to Renal Lesions (TIGER)

IgA Nephropathy

France
Ana Palanca

Completed

Real-world Evaluation of GLP-1 Receptor Agonists (GLP-1RA) on Efficacy and Persistence, Adherence and Therapeutic Inertia Among Type 2 Diabetes Adults With Obesity

Obesity | Type 2 Diabetes

Spain
Dasman Diabetes Institute

Completed

Obesity Treatment to Improve Diabetes (OTID)

Type 1 Diabetes

Kuwait
Samsung Medical Center

Not yet recruiting

The Efficacy of Enavogliflozin in Heart Failure With Preserved Ejection Fraction (ENRICH-PEF)

Heart Failure, Preserved Ejection Fraction

Korea, Republic of
Pfizer

Completed

Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis

Nonalcoholic Fatty Liver Disease | Nonalcoholic Steatohepatitis

United States, Canada
Brigham and Women's Hospital
Eli Lilly and Company; Boehringer Ingelheim

Recruiting

COPILOT-HF: Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure (COPILOT-HF)

Heart Failure

United States
University of Campania "Luigi Vanvitelli"

Completed

Sodium-glucose Co-transporter 2 Inhibitors Effects in Failing Heart Patients

Heart Failure | Diabetes Mellitus | Ventricular Arrythmia

Italy
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
Bayer

Completed

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results (FLAMINGO)

Type 2 Diabetes | Chronic Kidney Disease

United States
Kaiser Permanente
Patient-Centered Outcomes Research Institute; Henry Ford Health System; HealthPartners... and other collaborators

Recruiting

Comparison of Type 2 Diabetes Pharmacotherapy Regimens (ON TARGET DM)

Cardiovascular Diseases | Type 2 Diabetes Mellitus

United States
University of Texas Southwestern Medical Center

Recruiting

Effect of SGLT2i on Cardiovascular Biomarkers in Patients With Type 2 Diabetes and CKD Stage 3b-4

Diabetes | Kidney Disease, Chronic

United States
Hamad Medical Corporation

Recruiting

Impact of Sodium-glucose Cotransporter 2 Inhibitors on Post-operative Atrial Fibrillation in Cardiothoracic Surgery

Atrial Fibrillation

Qatar
University of Minnesota

Not yet recruiting

SGLT2 Inhibitors After Acute Kidney Injury With Indications Pilot

Acute Kidney Injury
Jeil Pharmaceutical Co., Ltd.

Completed

To Evaluate the Safety and Pharmacokinetic Characteristics After the Administration of JT-001, JT-002 and JLP-2008

Healthy Adult

Korea, Republic of
Ewha Womans University Mokdong Hospital

Enrolling by invitation

The Effect of SGLT-2 Inhibitor in Patient With Atrial Fibrillation and Diabetes Mellitus

Diabetes Mellitus, Type 2 | Atrial Fibrillation | SGLT-2 Inhibitor

Korea, Republic of
Dongying Zhang

Recruiting

Role of SGLT2I in Patients With Myocardial Infarction

Myocardial Infarction | Diabetes Mellitus

China
University of Palermo
Azienda Ospedaliera Ospedali Riuniti Villa Sofia Cervello

Recruiting

SGLT-2 Inhibitors in the Treatment of Ascites

Cirrhosis, Liver | Ascites Hepatic | Diabete Type 2

Italy
University of Aarhus
Aarhus University Hospital

Recruiting

Effect of Dapagliflozin on Myocardial and Renal Function Following Aortic Valve Stenosis Intervention (DAPAS)

Aortic Stenosis | Left Ventricle Hypertrophied

Denmark
University of Oxford

Completed

SGLT2 Inhibitors and Metformin on Metabolism and Non-Alcoholic SteatoHepatitis (SMASH)

Non-alcoholic Fatty Liver Disease

United Kingdom
Aswan University

Not yet recruiting

Effect of Sodium Glucose Co-transporter 2 Inhibitors on Left Atrial Remodeling

Atrial Fibrillation
Assiut University

Not yet recruiting

Gliflozins on HF in Regurgitant Rheumatic Heart

Heart Failure | Rheumatic Heart Disease
Samsung Medical Center

Recruiting

Peri-treatment of SGLT-2 Inhibitor on Myocardial Infarct Size and Remodeling Index in Patients With Acute Myocardial Infarction and High Risk of Heart Failure Undergoing Percutaneous Coronary Intervention (PRESTIGE-AMI)

Heart Failure | Acute Myocardial Infarction

Korea, Republic of
Nanjing First Hospital, Nanjing Medical University

Unknown

Effect of SGLT2 Inhibitor on Blood Glucose Profile in Type 2 Diabetic Patients Using Basal Insulin

Type2 Diabetes
Pharmaceuticals and Medical Devices Agency, Japan

Unknown

Meta-analysis in Post-marketing Surveillances for SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Theracos

Completed

Study to Determine the Safety, Tolerability, and Pharmacokinetic (PK) Profile of EGT0001474 in Healthy Volunteers

Safety and Tolerability of EGT0001474 in Healthy Volunteers

United States
LMC Diabetes & Endocrinology Ltd.
Merck Sharp & Dohme LLC; Syreon Corporation

Withdrawn

Approaches To Therapy Escalation In T2D (ATTACC)

Type2 Diabetes
University of Michigan
University of Colorado, Denver; Renal Pre-Competitive Consortium (RPC3)

Recruiting

Renal Mechanism of SGLT2 Inhibition

Diabetic Kidney Disease | Type 2 Diabetes

United States
Translational Research Center for Medical Innovation...
Astellas Pharma Inc; Osaka Saiseikai Nakatsu Hospital

Completed

Investigation for Clinical Efficacy and Safety of Ipragliflozin 50mg and 100mg on Type II Diabetes (HARUKAS)

Diabetes Mellitus, Type 2

Japan
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Effects of the Sodium-glucose Cotransporter 2 Inhibitors+Sacubitril/Valsartan Therapy in Patients With HFrEF.

Heart Failure | Ventricular Dysfunction | Ventricular Remodeling

Italy
Assiut University

Not yet recruiting

Using of SGLt2 Inhibitors in Patients With Type 2 DM

Type 2 Diabetes
Zealand University Hospital

Not yet recruiting

Treatment With SGLT-2 Inhibitor for Postoperative Hyperglycemia in Acute Abdominal Surgery - a Randomized Trial

Stress Hyperglycemia | Postoperative Hyperglycemia
West China Hospital

Not yet recruiting

Ameliorating Metabolic Profiling After Kidney Transplantation (AMPKT)

Kidney Transplantation | Metabolic Disorder | Metformin | Empagliflozin
Yaounde Central Hospital

Completed

Short Term Effect of Empagliflozin in Hypertension (EMPHYT)

Hypertension

Cameroon
Theracos

Completed

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

Diabetes Mellitus Type 2

United States
Amir Moheet

Recruiting

SGLT2 Inhibitor Therapy in Cystic Fibrosis-related Diabetes

Cystic Fibrosis | Cystic Fibrosis-related Diabetes

United States
The University of The West Indies

Completed

The Effect of empagliFlozin on Platelet Function profilEs in diabetiC patienTs - The EFFECT Study. (EFFECT)

Platelet Dysfunction Due to Drugs

Trinidad and Tobago
Iain Bressendorff

Recruiting

Feasibility of Aggressive Albuminuria Reduction in Biopsy-Proven Diabetic Nephropathy - A Pilot Study (WP3)

Diabetic Kidney Disease

Denmark
Queen's University, Belfast
Belfast Health and Social Care Trust

Recruiting

Investigation of Biomarker Response to SGLT2 Inhibition in Heart Failure (SiN-HF)

Heart Failure

United Kingdom
Boston University
American Heart Association

Recruiting

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes (SFRNDM2)

Diabetes Mellitus, Type 2 | Endothelial Dysfunction

United States
Federico II University

Completed

Clinical and Echocardiographic Management of Patients With Heart Failure and Diabetes: SCODIAC Follow up Study

Heart Failure | Diabetes

Italy
Stanford University
Merck Sharp & Dohme LLC

Active, not recruiting

Ertugliflozin: Cardioprotective Effects on Epicardial Fat

Cardiovascular Diseases | Atherosclerosis | Insulin Resistance | Type 2 Diabetes

United States
Fayoum University
Cairo University

Not yet recruiting

SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?

SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
The George Institute
University Medical Center Groningen; Australian and New Zealand Intensive Care...

Recruiting

PREVENTion With Sglt-2 Inhibition of Acute Kidney Injury in Intensive Care (PREVENTS-AKI)

Acute Kidney Injury

Australia
University of Patras

Recruiting

SGLT2 Inhibitors and Hemoglobin (SGLT2HgB)

Diabetes Mellitus, Type 2

Greece

Search clinical trials for: SGLT2i

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations